The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially benefiting millions of Americans struggling with obesity.

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington Post reported on Friday, citing documents from the Centers for Medicare and Medicaid Services.

The Trump administration is preparing a five-year pilot program that could allow Medicare and Medicaid to cover expensive GLP-1 weight loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound. If implemented,